Symbols / VCNX $0.95 -5.00% Vaccinex, Inc.
VCNX Chart
About
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Fundamentals
Scroll to Statements| Market Cap | 2.54M | Enterprise Value | 3.13M | Income | -18.63M | Sales | 601.00K | Book/sh | -1.55 | Cash/sh | 0.41 |
| Dividend Yield | — | Payout | 0.00% | Employees | 23 | IPO | — | P/E | — | Forward P/E | -6.79 |
| PEG | — | P/S | 4.23 | P/B | -0.61 | P/C | — | EV/EBITDA | -0.17 | EV/Sales | 5.20 |
| Quick Ratio | 0.38 | Current Ratio | 0.50 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -8.88 | EPS next Y | -0.14 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2021-08-16 | ROA | -3.76% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -15.90% | Profit Margin | 0.00% | Shs Outstand | 2.68M | Shs Float | 1.18M | Short Float | 3.23% |
| Short Ratio | 0.60 | Short Interest | — | 52W High | 1.50 | 52W Low | 0.31 | Beta | 0.71 | Avg Volume | 2.94K |
| Volume | 3.35K | Target Price | — | Recom | None | Prev Close | $1.00 | Price | $0.95 | Change | -5.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan Fri, 07 Mar 2025 08
- VCNX Stock Price and Chart — OTC:VCNX - TradingView hu, 19 Dec 2024 21
- Vaccinex Stock Price Forecast. Should You Buy VCNX? - StockInvest.us ue, 01 Dec 2020 21
- Vaccinex (VCNX) Stock Price, News & Analysis - MarketBeat Fri, 10 Aug 2018 22
- Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology Mon, 10 Mar 2025 07
- Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc - Yahoo Finance Mon, 12 Feb 2024 08
- Latest VCNX News - Vaccinex, Inc. Announces $60 million Agreem... - Stock Titan Mon, 14 Sep 2020 09
- The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. - ChartMill Fri, 01 Sep 2023 07
- Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today? - InvestorPlace ue, 07 Feb 2023 08
- 3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions - InvestorPlace hu, 20 Jun 2024 07
- Vaccinex Announces up to $16.5 Million in Equity Financing - GlobeNewswire ue, 31 Mar 2020 07
Insider Transactions
Financials
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.60
+5.44%
|
0.57
+107.27%
|
0.28
-69.44%
|
0.90
|
| Operating Revenue |
|
0.60
+5.44%
|
0.57
+107.27%
|
0.28
-69.44%
|
0.90
|
| Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Gross Profit |
|
—
|
—
|
—
|
0.90
|
| Operating Expense |
|
19.34
-17.56%
|
23.45
+16.22%
|
20.18
-13.72%
|
23.39
|
| Research And Development |
|
12.54
-24.31%
|
16.57
+18.56%
|
13.98
-18.54%
|
17.16
|
| Selling General And Administration |
|
6.79
-1.31%
|
6.88
+10.95%
|
6.20
-0.45%
|
6.23
|
| General And Administrative Expense |
|
6.79
-1.31%
|
6.88
+10.95%
|
6.20
-0.45%
|
6.23
|
| Other Gand A |
|
6.79
-1.31%
|
6.88
+10.95%
|
6.20
-0.45%
|
6.23
|
| Other Operating Expenses |
|
—
|
—
|
-0.17
|
—
|
| Total Expenses |
|
19.34
-17.56%
|
23.45
+16.22%
|
20.18
-13.72%
|
23.39
|
| Operating Income |
|
-18.73
+18.13%
|
-22.89
-14.97%
|
-19.91
+11.49%
|
-22.49
|
| Total Operating Income As Reported |
|
-18.73
+18.13%
|
-22.89
-14.97%
|
-19.91
+11.49%
|
-22.49
|
| EBITDA |
|
-18.54
+7.91%
|
-20.13
-2.68%
|
-19.61
+8.39%
|
-21.40
|
| Normalized EBITDA |
|
-18.60
+14.89%
|
-21.85
-11.47%
|
-19.61
+11.99%
|
-22.28
|
| Reconciled Depreciation |
|
0.09
-21.01%
|
0.12
-42.51%
|
0.21
+22.49%
|
0.17
|
| EBIT |
|
-18.63
+7.99%
|
-20.25
-2.21%
|
-19.81
+8.15%
|
-21.57
|
| Total Unusual Items |
|
0.06
-96.40%
|
1.72
|
0.00
-100.00%
|
0.88
|
| Total Unusual Items Excluding Goodwill |
|
0.06
-96.40%
|
1.72
|
0.00
-100.00%
|
0.88
|
| Special Income Charges |
|
—
|
—
|
0.00
-100.00%
|
0.88
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.88
|
| Net Income |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Pretax Income |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Net Non Operating Interest Income Expense |
|
-0.00
-100.00%
|
-0.00
+50.00%
|
-0.00
+99.75%
|
-0.81
|
| Interest Expense Non Operating |
|
0.00
+100.00%
|
0.00
-50.00%
|
0.00
-99.75%
|
0.81
|
| Net Interest Income |
|
-0.00
-100.00%
|
-0.00
+50.00%
|
-0.00
+99.75%
|
-0.81
|
| Interest Expense |
|
0.00
+100.00%
|
0.00
-50.00%
|
0.00
-99.75%
|
0.81
|
| Other Income Expense |
|
0.10
-96.09%
|
2.63
+2733.33%
|
0.09
-89.88%
|
0.92
|
| Other Non Operating Income Expenses |
|
0.04
-95.50%
|
0.91
+880.65%
|
0.09
+116.28%
|
0.04
|
| Gain On Sale Of Security |
|
0.06
-96.40%
|
1.72
|
—
|
—
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Net Income From Continuing Operation Net Minority Interest |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Net Income From Continuing And Discontinued Operation |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Net Income Continuous Operations |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Minority Interests |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-18.70
+14.92%
|
-21.97
-10.90%
|
-19.82
+14.80%
|
-23.26
|
| Net Income Common Stockholders |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Diluted EPS |
|
—
|
-43.68
+55.45%
|
-98.05
+40.14%
|
-163.80
|
| Basic EPS |
|
—
|
-43.68
+55.45%
|
-98.05
+40.14%
|
-163.80
|
| Basic Average Shares |
|
—
|
0.46
+129.44%
|
0.20
+47.10%
|
0.14
|
| Diluted Average Shares |
|
—
|
0.46
+129.44%
|
0.20
+47.10%
|
0.14
|
| Diluted NI Availto Com Stockholders |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
2.60
-28.50%
|
3.63
-54.48%
|
7.98
-18.96%
|
9.84
|
| Current Assets |
|
2.53
-24.43%
|
3.35
-55.22%
|
7.48
-20.49%
|
9.40
|
| Cash Cash Equivalents And Short Term Investments |
|
1.11
-27.88%
|
1.53
-75.98%
|
6.39
-25.59%
|
8.59
|
| Cash And Cash Equivalents |
|
1.11
-27.88%
|
1.53
-75.98%
|
6.39
-25.59%
|
8.59
|
| Receivables |
|
0.84
-12.80%
|
0.96
+449.14%
|
0.17
|
0.00
|
| Accounts Receivable |
|
0.84
-12.80%
|
0.96
+449.14%
|
0.17
|
0.00
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.82
|
| Hedging Assets Current |
|
0.00
|
0.00
|
—
|
—
|
| Other Current Assets |
|
0.59
-31.30%
|
0.85
-6.47%
|
0.91
+11.76%
|
0.82
|
| Total Non Current Assets |
|
0.07
-77.03%
|
0.28
-43.29%
|
0.50
+13.93%
|
0.44
|
| Net PPE |
|
0.07
-77.03%
|
0.28
-43.29%
|
0.50
+13.93%
|
0.44
|
| Gross PPE |
|
7.25
-1.68%
|
7.37
-4.91%
|
7.75
+3.58%
|
7.49
|
| Accumulated Depreciation |
|
-7.18
-1.33%
|
-7.09
+2.27%
|
-7.26
-2.94%
|
-7.05
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.60
+0.00%
|
0.60
-10.58%
|
0.67
+5.84%
|
0.63
|
| Other Properties |
|
3.37
-3.55%
|
3.50
-8.58%
|
3.83
+5.08%
|
3.64
|
| Leases |
|
3.28
+0.00%
|
3.28
+0.55%
|
3.26
+1.43%
|
3.21
|
| Total Liabilities Net Minority Interest |
|
5.08
-14.44%
|
5.94
+113.43%
|
2.78
+14.52%
|
2.43
|
| Current Liabilities |
|
5.08
-14.06%
|
5.92
+133.19%
|
2.54
+12.46%
|
2.26
|
| Payables And Accrued Expenses |
|
5.06
+54.19%
|
3.28
+42.71%
|
2.30
+12.64%
|
2.04
|
| Payables |
|
3.96
+93.97%
|
2.04
+34.32%
|
1.52
+43.07%
|
1.06
|
| Accounts Payable |
|
3.96
+93.97%
|
2.04
+34.32%
|
1.52
+43.07%
|
1.06
|
| Current Accrued Expenses |
|
1.10
-11.11%
|
1.24
+59.03%
|
0.78
-20.31%
|
0.98
|
| Current Debt And Capital Lease Obligation |
|
0.03
-88.69%
|
0.22
-7.14%
|
0.24
+10.70%
|
0.21
|
| Current Debt |
|
0.03
-66.67%
|
0.07
+1.35%
|
0.07
+0.00%
|
0.07
|
| Other Current Borrowings |
|
0.03
-66.67%
|
0.07
+1.35%
|
0.07
+0.00%
|
0.07
|
| Current Capital Lease Obligation |
|
0.00
-100.00%
|
0.15
-10.98%
|
0.16
+16.31%
|
0.14
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
0.06
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.00
-100.00%
|
0.06
|
0.00
|
—
|
| Other Current Liabilities |
|
—
|
2.35
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.03
-89.47%
|
0.25
+41.14%
|
0.17
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.03
-89.47%
|
0.25
+41.14%
|
0.17
|
| Long Term Debt |
|
—
|
0.03
-74.26%
|
0.10
-42.29%
|
0.17
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.15
|
0.00
|
| Stockholders Equity |
|
-2.49
-7.66%
|
-2.31
-144.50%
|
5.19
-29.94%
|
7.41
|
| Common Stock Equity |
|
-4.15
-79.71%
|
-2.31
-144.50%
|
5.19
-29.94%
|
7.41
|
| Capital Stock |
|
1.67
|
0.00
|
0.00
-100.00%
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Preferred Stock |
|
1.67
|
0.00
|
—
|
—
|
| Share Issued |
|
2.68
+199.86%
|
0.89
+275.79%
|
0.24
+61.94%
|
0.15
|
| Ordinary Shares Number |
|
2.68
+199.86%
|
0.89
+275.80%
|
0.24
+61.95%
|
0.15
|
| Treasury Shares Number |
|
0.00
+25.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
354.42
+4.97%
|
337.63
+3.92%
|
324.88
+5.73%
|
307.28
|
| Retained Earnings |
|
-358.56
-5.48%
|
-339.93
-6.33%
|
-319.68
-6.61%
|
-299.86
|
| Treasury Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Minority Interest |
|
—
|
—
|
—
|
0.00
|
| Total Equity Gross Minority Interest |
|
-2.49
-7.66%
|
-2.31
-144.50%
|
5.19
-29.94%
|
7.41
|
| Total Capitalization |
|
-2.49
-8.88%
|
-2.29
-143.16%
|
5.29
-30.22%
|
7.59
|
| Working Capital |
|
-2.55
+0.55%
|
-2.57
-151.95%
|
4.94
-30.89%
|
7.15
|
| Invested Capital |
|
-4.13
-86.79%
|
-2.21
-141.17%
|
5.37
-29.93%
|
7.66
|
| Total Debt |
|
0.03
-89.88%
|
0.25
-49.07%
|
0.48
+24.36%
|
0.39
|
| Capital Lease Obligations |
|
0.00
-100.00%
|
0.15
-52.90%
|
0.31
+119.86%
|
0.14
|
| Net Tangible Assets |
|
-2.49
-7.66%
|
-2.31
-144.50%
|
5.19
-29.94%
|
7.41
|
| Tangible Book Value |
|
-4.15
-79.71%
|
-2.31
-144.50%
|
5.19
-29.94%
|
7.41
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Equity |
|
1.67
|
—
|
—
|
—
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-16.19
+24.29%
|
-21.38
-12.08%
|
-19.07
+24.60%
|
-25.30
|
| Cash Flow From Continuing Operating Activities |
|
-16.19
+24.29%
|
-21.38
-12.08%
|
-19.07
+24.60%
|
-25.30
|
| Net Income From Continuing Operations |
|
-18.63
+7.98%
|
-20.25
-2.20%
|
-19.82
+11.46%
|
-22.38
|
| Depreciation Amortization Depletion |
|
0.09
-21.01%
|
0.12
-42.51%
|
0.21
+22.49%
|
0.17
|
| Depreciation |
|
0.09
-21.01%
|
0.12
-42.51%
|
0.21
+22.49%
|
0.17
|
| Depreciation And Amortization |
|
0.09
-21.01%
|
0.12
-42.51%
|
0.21
+22.49%
|
0.17
|
| Other Non Cash Items |
|
-1.29
+38.70%
|
-2.11
|
—
|
0.46
|
| Stock Based Compensation |
|
0.34
-28.06%
|
0.47
-13.03%
|
0.55
+0.74%
|
0.54
|
| Operating Gains Losses |
|
1.20
+1692.54%
|
0.07
|
—
|
-0.88
|
| Gain Loss On Investment Securities |
|
1.20
+1692.54%
|
0.07
|
—
|
—
|
| Change In Working Capital |
|
2.10
+561.32%
|
0.32
+2990.91%
|
-0.01
+99.66%
|
-3.21
|
| Change In Receivables |
|
0.12
+115.65%
|
-0.79
-349.14%
|
-0.17
-211.46%
|
0.16
|
| Changes In Account Receivables |
|
0.12
+115.65%
|
-0.79
-349.14%
|
-0.17
-211.46%
|
0.16
|
| Change In Prepaid Assets |
|
0.27
+352.54%
|
0.06
+162.77%
|
-0.09
+68.87%
|
-0.30
|
| Change In Payables And Accrued Expense |
|
1.78
+80.86%
|
0.98
+280.62%
|
0.26
+108.42%
|
-3.06
|
| Change In Accrued Expense |
|
-0.14
-129.93%
|
0.46
+331.66%
|
-0.20
+79.21%
|
-0.96
|
| Change In Payable |
|
1.91
+267.37%
|
0.52
+14.00%
|
0.46
+121.68%
|
-2.11
|
| Change In Account Payable |
|
1.91
+267.37%
|
0.52
+14.00%
|
0.46
+121.68%
|
-2.11
|
| Change In Other Working Capital |
|
-0.06
-200.00%
|
0.06
|
—
|
—
|
| Investing Cash Flow |
|
-0.02
+67.16%
|
-0.07
+32.32%
|
-0.10
-209.38%
|
-0.03
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
+67.16%
|
-0.07
+32.32%
|
-0.10
-209.38%
|
-0.03
|
| Net PPE Purchase And Sale |
|
-0.02
+67.16%
|
-0.07
+32.32%
|
-0.10
-209.38%
|
-0.03
|
| Purchase Of PPE |
|
-0.02
+67.16%
|
-0.07
+32.32%
|
-0.10
-209.38%
|
-0.03
|
| Capital Expenditure |
|
-0.02
+67.16%
|
-0.07
+32.32%
|
-0.10
-209.38%
|
-0.03
|
| Financing Cash Flow |
|
15.78
-4.88%
|
16.59
-2.27%
|
16.98
-27.22%
|
23.32
|
| Cash Flow From Continuing Financing Activities |
|
15.78
-4.88%
|
16.59
-2.27%
|
16.98
-27.22%
|
23.32
|
| Net Issuance Payments Of Debt |
|
-0.08
-2.70%
|
-0.07
+1.33%
|
-0.07
+99.12%
|
-8.54
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
-0.08
-2.70%
|
-0.07
+1.33%
|
-0.07
+99.12%
|
-8.54
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
-0.08
-2.70%
|
-0.07
+1.33%
|
-0.07
+99.12%
|
-8.54
|
| Net Long Term Debt Issuance |
|
-0.08
-2.70%
|
-0.07
+1.33%
|
-0.07
+99.12%
|
-8.54
|
| Net Common Stock Issuance |
|
7.12
-41.95%
|
12.27
-28.02%
|
17.05
-48.09%
|
32.85
|
| Proceeds From Stock Option Exercised |
|
7.03
+60.19%
|
4.39
|
—
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.98
|
| Changes In Cash |
|
-0.43
+91.19%
|
-4.86
-120.93%
|
-2.20
-9.52%
|
-2.01
|
| Beginning Cash Position |
|
1.53
-75.98%
|
6.39
-25.59%
|
8.59
-18.94%
|
10.60
|
| End Cash Position |
|
1.11
-27.88%
|
1.53
-75.98%
|
6.39
-25.59%
|
8.59
|
| Free Cash Flow |
|
-16.21
+24.42%
|
-21.45
-11.86%
|
-19.17
+24.31%
|
-25.33
|
| Common Stock Issuance |
|
7.12
-41.95%
|
12.27
-28.02%
|
17.05
-48.09%
|
32.85
|
| Issuance Of Capital Stock |
|
8.82
-28.12%
|
12.27
-28.02%
|
17.05
-48.09%
|
32.85
|
| Net Preferred Stock Issuance |
|
1.70
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
1.70
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2025-04-15 View
- 8-K2025-03-19 View
- 8-K2025-03-07 View
- 8-K2024-12-17 View
- 42024-11-18 View
- 42024-11-18 View
- 8-K2024-11-14 View
- 10-Q2024-11-14 View
- 8-K2024-10-09 View
- 42024-09-20 View
- 42024-09-20 View
- 8-K2024-09-19 View
- 8-K2024-09-13 View
- 8-K2024-08-20 View
- 10-Q2024-08-14 View
- 8-K2024-08-14 View
- 42024-08-13 View
- 42024-08-07 View
- 42024-08-02 View
- 42024-08-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|